Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization

Taiwanese Journal of Obstetrics and Gynecology

Volumn 47, Issue 1, 2008, Pages 66-74

  Hsieh, Yao Yuan ^a   Chang, Chi Chen ^a   Tsai, Horng Der ^b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Cetrorelix; GnRH agonist; GnRH antagonist; Leuprolide acetate; Pituitary suppression

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; UTROGESTON;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; HYPOPHYSIS FUNCTION; INTRACYTOPLASMIC SPERM INJECTION; LUTEOLYSIS; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OPEN STUDY; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 42949105699     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(08)60057-1     Document Type: Article

References (59)

1. J Testart B Lefevre A Gougeon Effects of gonadotrophinreleasing hormone agonists (GnRHa) on follicle and oocyte quality Hum Reprod 8 1993 511 518
2. J Tapanainen O Hovatta K Juntunen H Martikainen K Ratsula M Tulppala L Tuomivaara Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study Hum Reprod 8 1993 2052 2055
3. F Devreker I Govaerts E Bertrand M Van den Bergh C Gervy Y Englert The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate Fertil Steril 65 1996 122 126
4. Y Hsieh H Tsai C Chang H Lo Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program Fertil Steril 73 2000 817 820
5. A Hazout D de Ziegler C Cornel H Fernandez C Lelaidier R Frydman Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation Fertil Steril 59 1993 596 600
6. F Olivennes R Fanchin P Bouchard J Taieb R Frydman Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist Fertil Steril 66 1996 151 153
7. K Diedrich C Diedrich E Santos Suppression of the endogenous luteinizing hormone surge by the gonadotrophinreleasing hormone antagonist Cetrorelix during ovarian stimulation Hum Reprod 9 1994 788 791
8. R Felberbaum T Reissmann W Kupker Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages J Assist Reprod Genet 13 1996 216 222
9. G Borm B Mannaerts The European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial Hum Reprod 15 2000 1490 1498
10. C Albano J Smitz M Camus H Riethmuller-Winzen A Van Steirteghem P Devroey Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation Fertil Steril 67 1997 917 922
11. C Albano J Smitz H Tournaye H Riethmuller-Winzen A Van Steirteghem P Devroey Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles Hum Reprod 14 1999 1426 1430
12. JL Hwang KM Seow YH Lin Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study Hum Reprod 19 2004 1993 2000
13. TH Lee MY Wu HF Chen MJ Chen HN Ho YS Yang Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration Fertil Steril 83 2005 1700 1707
14. J Itskovitz-Eldor S Kol B Mannaerts H Coelingh Bennink First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) Hum Reprod 13 1998 294 295
15. A Weghofer M Margreiter S Bassim U Sevelda E Beilhack W Feichtinger Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age Fertil Steril 81 2004 1002 1006
16. AJ Rutherford RJ Subak-Sharpe KJ Dawson RA Margara S Franks RML Winston Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormone Br Med J (Clin Res Ed) 296 1988 1765 1768
17. SK Wasser G Sewall MR Soules Psychosocial stress as a cause of infertility Fertil Steril 59 1993 685 689
18. L Gianaroli AP Ferraretti E Feliciani C Tabanelli C Magli D Fortini Prospective randomized study of D-Trp6-LHRH versus buserelin in long desensitization protocols for medically assisted conception cycles Hum Reprod 9 1994 220 225
19. LE Albuquerque H Saconato MC Maciel Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles Cochrane Database Syst Rev 3 2002 CD002808
20. E Porcu L Dal Prato R Seracchioli R Fabbri M Longhi C Flamigni Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results Fertil Steril 62 1994 126 132
21. M Dhont A Onghena T Coetsier P De Sutter Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction Hum Reprod 10 1995 791 796
22. F Neuspiller M Levy J Remohi A Ruiz C Simon A Pellicer The use of long- and short-acting forms of gonadotrophinreleasing hormone analogues in women undergoing oocyte donation Hum Reprod 13 1998 1148 1151
23. T Dada O Salha HS Baillie V Sharma A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study Hum Reprod 14 1999 288 293
24. A Simon A Benshushan A Shushan G Zajicek D Dorembus A Lewin N Laufer A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization Hum Reprod 9 1994 1813 1817
25. J Balasch F Gomez R Casamitjana F Carmona F Rivera JA Vanrell Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot Hum Reprod 7 1992 1230 1234
26. HD Tsai CM Chen HY Lo CC Chang Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization Hum Reprod 10 1995 2909 2912
27. E Shalev PC Leung Gonadotropin-releasing hormone and reproductive medicine J Obstet Gynaecol Can 25 2003 98 113
28. VY Fujimoto SE Monroe LR Nelson D Downey RB Jaffe Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray Fertil Steril 67 1997 469 473
29. JJ Oberye BM Mannaerts JA Huisman CJ Timmer Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers Fertil Steril 72 1999 1006 1012
30. M Plachot Biological assessment criteria during antagonist protocols J Gynecol Obstet Biol Reprod (Paris) 33 2004 3S32 3S35 [In French]
31. RE Felberbaum K Diedrich Gonadotrophin-releasing hormone antagonists: will they replace the agonists? Reprod Biomed Online 6 2003 43 53
32. LP Cheung PM Lam IH Lok TT Chiu SY Yeung CC Tjer CJ Haines GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial Hum Reprod 20 2005 616 621
33. R Roulier V Chabert-Orsini MC Sitri B Barry P Terriou Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3mg) in patients undergoing assisted reproduction treatment Reprod Biomed Online 7 2003 185 189
34. EH Ng PC Ho Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in-vitro fertilization treatment: multiple doses and single dose J Obstet Gynaecol Res 27 2001 261 265
35. K Gordon RF Williams DR Danforth GD Hodgen A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction Fertil Steril 54 1990 1140 1145
36. RT Mansour MA Aboulghar GI Serour HG Al-Inany YM Amin AM Abou-Setta The use of gonadotropin-releasing hormone antagonist in a flexible protocol: a pilot study Am J Obstet Gynecol 189 2003 444 446
37. M Ludwig A Katalinic K Diedrich Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis Arch Gynecol Obstet 265 2001 175 182
38. C Albano RE Felberbaum J Smitz H Riethmuller-Winzen J Engel K Diedrich P Devroey Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group Hum Reprod 15 2000 526 531
39. ML Check JH Check JK Choel E Davies D Kiefer Effect of antagonists vs agonists on in vitro fertilization outcome Clin Exp Obstet Gynecol 31 2004 257 259
40. F Olivennes J Belaisch-Allart JC Emperaire Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin) Fertil Steril 73 2000 314 320
41. SJ Fasouliotis N Laufer S Sabbagh-Ehrlich A Lewin A Hurwitz A Simon Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF J Assist Reprod Genet 20 2003 455 460
42. K Zikopoulos A Kaponis G Adonakis A Sotiriadis S Kalantaridou I Georgiou E Paraskevaidis A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia Fertil Steril 83 2005 1354 1362
43. K Takahashi T Mukaida T Tomiyama T Goto C Oka GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol J Assist Reprod Genet 21 2004 317 322
44. The ganirelix dose-finding study group A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon) Hum Reprod 13 1998 3023 3031
45. BC Fauser P Devroey SS Yen R Gosden WF Crowley Jr DT Baird P Bouchard Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks Hum Reprod 14 1999 2681 2686
46. M Ludwig RE Felberbaum P Devroey Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction Arch Gynecol Obstet 264 2000 29 32
47. H Al-Inany M Aboulghar Gonadotrophin-releasing hormone antagonists for assisted conception Cochrane Database Syst Rev 4 2001 CD001750
48. V Vlaisavljevic M Reljic VG Lovrec B Kovacic Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles–a prospective, randomized study Reprod Biomed Online 7 2003 301 308
49. P Bouchard BC Fauser Gonadotropin-releasing hormone antagonist: new tools vs. old habits Fertil Steril 73 2000 18 20
50. PE Levi-Setti M Cavagna C Bulletti Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH Eur J Obstet Gynecol Reprod Biol 126 2006 212 216
51. C Wang AJ Hsueh GF Erickson LH stimulation of estrogen secretion by cultured rat granulosa cells Mol Cell Endocrinol 24 1981 17 28
52. E Escudero E Bosch J Crespo C Simon J Remohi A Pellicer Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients Fertil Steril 81 2004 562 566
53. JB Engel M Ludwig K Junge CM Howles K Diedrich No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multipledose protocols Reprod Biomed Online 6 2003 482 487
54. H Al-Inany M Aboulghar GnRH antagonist in assisted reproduction: a Cochrane review Hum Reprod 17 2002 874 885
55. JL Hwang LW Huang BC Hsieh Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles Hum Reprod 18 2003 45 49
56. BC Fauser P Devroey Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 83 2005 1607 1611
57. P Saadat R Boostanfar CC Slater DE Tourgeman FZ Stanczyk RJ Paulson Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists Fertil Steril 82 2004 167 171
58. A Herman A Raziel D Strassburger Y Soffer I Bukovsky R Ron-El The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a downregulation protocol and luteal support with progesterone Hum Reprod 11 1996 1552 1557
59. R Felberbaum K Diedrich Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists Hum Reprod 14 Suppl 1 1999 207 221